The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 31, 2018

Filed:

Nov. 10, 2015
Applicant:

Biodesix, Inc., Boulder, CO (US);

Inventors:

Joanna Röder, Steamboat Springs, CO (US);

Carlos Oliveira, Steamboat Springs, CO (US);

Julia Grigorieva, Steamboat Springs, CO (US);

Heinrich Röder, Steamboat Springs, CO (US);

Devalingam Mahalingam, San Antonio, TX (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
H01J 49/00 (2006.01); H01J 49/16 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G06K 9/62 (2006.01); G16H 50/70 (2018.01); G16H 10/40 (2018.01); G06K 9/00 (2006.01);
U.S. Cl.
CPC ...
H01J 49/0036 (2013.01); G01N 33/57438 (2013.01); G01N 33/6851 (2013.01); G06K 9/00147 (2013.01); G06K 9/6228 (2013.01); G06K 9/6276 (2013.01); G16H 10/40 (2018.01); G16H 50/70 (2018.01); H01J 49/164 (2013.01); G06K 9/00536 (2013.01); Y02A 90/26 (2018.01);
Abstract

Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.


Find Patent Forward Citations

Loading…